^
    2ms
    TmPSMA-02 in mCRPC (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting | N=18 --> 8
    Enrollment closed • Enrollment change
    |
    TmPSMA-02
    5ms
    Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • engineered autologous T cells
    6ms
    Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging. (PubMed, Proc Natl Acad Sci U S A)
    Herein, we develop an approach for in situ T cell generation, tracking, and functional assessment using anti-CD5-conjugated lipid nanoparticles for codelivering CD19 CAR mRNA (mCAR19) and a prostate-specific membrane antigen mRNA (mPSMA) tag. With interleukin-7 (IL-7) preconditioning and repeated administration, this approach achieves tumor-free survival in 75% of B cell lymphoma-bearing mice (similar efficacy to ex vivo approaches), and through PET imaging of 68Ga-PSMA-617, the generation and tumor infiltration of in situ-engineered PSMA-tagged CD19 CAR-T cells is validated.
    Journal
    |
    IL7 (Interleukin 7)
    8ms
    Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC (clinicaltrials.gov)
    P1, N=3, Recruiting, Shanghai Changzheng Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    8ms
    Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC (clinicaltrials.gov)
    P1, N=3, Not yet recruiting, Shanghai Changzheng Hospital
    New P1 trial
    10ms
    P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) (clinicaltrials.gov)
    P1, N=40, Terminated, Poseida Therapeutics, Inc. | N=60 --> 40 | Trial completion date: Sep 2036 --> Sep 2024 | Active, not recruiting --> Terminated; Study closed
    Enrollment change • Trial completion date • Trial termination
    |
    rimiducid (AP1903)
    10ms
    GITRL enhances cytotoxicity and persistence of CAR-T cells in cancer therapy. (PubMed, Mol Ther)
    In addition, PSMA-BB-Z-GITRL CAR-T cells produce higher levels of IFN-γ, TNF-α and IL-9 in mouse blood, exhibiting a higher proportion of TCM cells and a lower proportion of Treg cells compared to PSMA-BB-Z CAR-T cells. Our results demonstrate that the overexpression of GITRL has important implications for improving CAR-T cell-based human solid tumor immunotherapy.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)
    1year
    CART-PSMA Cells for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=20, Recruiting, Nova Therapeutics LLC | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date • Metastases
    |
    FOLH1 expression
    |
    cyclophosphamide • CART-PSMA
    over1year
    Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    cyclophosphamide • engineered autologous T cells
    over1year
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (clinicaltrials.gov)
    P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2026 --> Aug 2036 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18) • AXL (AXL Receptor Tyrosine Kinase) • MSLN (Mesothelin) • CD276 (CD276 Molecule) • GPC3 (Glypican 3) • TGFB1 (Transforming Growth Factor Beta 1) • GUCY2C (Guanylate Cyclase 2C) • PSCA (Prostate Stem Cell Antigen 2)
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    over1year
    CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    FOLH1 expression
    |
    cyclophosphamide • fludarabine IV • CART-PSMA- TGFβRDN cells
    over1year
    Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker (clinicaltrials.gov)
    P1, N=16, Terminated, AvenCell Europe GmbH | N=51 --> 16 | Trial completion date: Jul 2025 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Mar 2024; Although IMP has been well tolerated, biological activity was very limited. The sponsor concluded that continued development of IMP would be unlikely to result in meaningful clinical benefit for patients with prostate cancer.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    cyclophosphamide • fludarabine IV